Country for PR: China
Contributor: PR Newswire Asia (China)
Thursday, January 27 2022 - 11:00
iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022
SEOUL, South Korea, Jan. 27, 2022 /PRNewswire-AsiaNet/ --

-An innovative  Wireless Brainwave Scanning & Mapping device Attracts the Media 
and Public Attention from Visitors Around the World  

iMediSync, A biotech startup company from Seoul, South Korea, successfully 
debuted at CES 2022 to introduce the new trend of digital healthcare under 
their motto – Overcome Mental Pandemic in just 10 Min.

At the event, the company presented iSyncWave, a dry EEG helmet that provides 
EEG, HRV measurement equipped with the world first age/gender matching Norm DB 
built with over 1,800 healthy brainwaves to provide a comparative analysis 
report to the subject.

iSyncWave's main features follow below: 

-Nineteen channel electrodes with gear that automatically adjust to the 10/20 
-Age/gender matching EEG and HRV analysis & assessment report in 10 minutes 
-PBM - Near InfraRed LED Therapy

During CES 2022, the company caught the attention of the media and visitors 
from all over the globe. Each day, more than three hundred visitors came to the 
booth including audiences such as doctors, clinicians, entrepreneurs, 
YouTubers, influencers, and interested parties. 

On the first day of CES, nearly one hundred visitors were able to participate 
in their real-time brainwave measurement and to learn more about the brain and 

A promising start for the iMediSync continued its momentum with interest from 
all kinds of audiences including the CTA VIP tours.

The CEO Dr. Seung Wan Kang comments, "The purpose of this showcase is to 
introduce our technology and our goal that we will provide life-changing mental 
healthcare experience in the field of neuro-mental illness biomarker with our 
patent EEG/HRV technology, we strive to provide an optimized individual mental 
healthcare service in the post-Covid-19 era." 

Aside from iMediSync's innovation and technology, the booth received numerous 
visits from key personnel to discuss collaboration in digital healthcare fields 
and to expand to the global market of brain science and neurology. 

iMediSync, expecting the IPO this year has established close cooperation with 
various research facilities and medical organization around the world is 
continuing discussion with major pharmaceutical companies for cooperation.

With the Korean FDA approval for their product and the software, iMediSync 
expects the FDA and CE approval in the first half of 2022 to expand further on 
their biomarkers along with developing a next-level product to declare 
themselves as a trend leader in the field.

Source: iMediSync

Image Attachments Links:


   Caption: Attendees waiting in the line to experience the iSyncWave at CES 


   Caption: Attendee experiencing the new iSyncWave at the iMediSync booth

image-1.jpg image-2.jpg